Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CFO Mardi Dier sold 1,183 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $427.21, for a total value of $505,389.43. Following the sale, the chief financial officer directly owned 9,257 shares of the company's stock, valued at approximately $3,954,682.97. This trade represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Mardi Dier also recently made the following trade(s):
- On Tuesday, December 2nd, Mardi Dier sold 4,173 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $578.34, for a total value of $2,413,412.82.
Madrigal Pharmaceuticals Stock Up 0.8%
Shares of NASDAQ:MDGL opened at $435.62 on Tuesday. The stock has a 50-day simple moving average of $506.15 and a 200-day simple moving average of $486.74. The stock has a market capitalization of $9.99 billion, a P/E ratio of -33.85 and a beta of -0.97. Madrigal Pharmaceuticals, Inc. has a 1 year low of $265.00 and a 1 year high of $615.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The business had revenue of $321.08 million during the quarter, compared to analysts' expectations of $310.36 million. During the same quarter in the previous year, the business posted ($2.71) EPS. The company's quarterly revenue was up 210.8% on a year-over-year basis. Equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Institutional investors have recently made changes to their positions in the company. Groupama Asset Managment lifted its stake in Madrigal Pharmaceuticals by 11.6% during the fourth quarter. Groupama Asset Managment now owns 30,620 shares of the biopharmaceutical company's stock worth $17,831,000 after purchasing an additional 3,176 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth $1,083,000. Invesco Ltd. lifted its position in shares of Madrigal Pharmaceuticals by 21.9% in the 4th quarter. Invesco Ltd. now owns 365,314 shares of the biopharmaceutical company's stock worth $212,737,000 after buying an additional 65,749 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Madrigal Pharmaceuticals in the 4th quarter valued at about $355,000. Finally, XTX Topco Ltd bought a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter valued at about $1,642,000. 98.50% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
MDGL has been the topic of several research reports. The Goldman Sachs Group reissued a "buy" rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday, January 14th. B. Riley Financial lifted their price objective on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a "buy" rating in a report on Thursday, December 11th. Barclays started coverage on Madrigal Pharmaceuticals in a research note on Tuesday, January 27th. They set an "overweight" rating and a $964.00 target price for the company. Zacks Research upgraded shares of Madrigal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, February 20th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $685.31.
Get Our Latest Stock Analysis on MDGL
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
